A Clinical Nomogram for Predicting Cancer-Specific Survival in Pulmonary Large-Cell Neuroendocrine Carcinoma Patients: A Population-Based Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:166–172.
   PubMed Web of Science ®Google Scholar
• Lázaro S, Pérez-Crespo M, Lorz C, et al. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes. Proc Natl Acad Sci. 2019;116:22300–22306.
   PubMed Web of Science ®Google Scholar
• Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10:1133–1141.
   PubMed Web of Science ®Google Scholar
• Raman V, Jawitz OK, Yang C-FJ, et al. Adjuvant therapy for patients with early large cell lung neuroendocrine cancer: a national analysis. Ann Thorac Surg. 2019;108:377–383.
   PubMed Web of Science ®Google Scholar
• Lo H, Abel S, Finley G, Weksler B, Colonias A, Wegner RE. Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma. Thoracic Cancer. 2020;11:305–310.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–e180.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Mayne N, Yang C-FJ, et al. A nomogram for predicting cancer-specific survival of TNM 8th edition stage I non-small-cell lung cancer. Ann Surg Oncol. 2019;26:2053–2062.
   PubMed Web of Science ®Google Scholar
• Xiang G-H, Zhu -J-J, Ke C-R, et al. Nomograms predict overall survival and cancer-specific survival in patients with fibrosarcoma: a seer-based study. J Oncol. 2020;2020. doi:10.1155/2020/8284931
   Web of Science ®Google Scholar
• Wang F, Zhang H, Wen J, et al. Nomograms forecasting long-term overall and cancer-specific survival of patients with oral squamous cell carcinoma. Cancer Med. 2018;7:943–952.
   PubMed Web of Science ®Google Scholar
• He Y, Liu H, Wang S, Chen Y. Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma. PLoS One. 2019;14:e0223275.
   PubMed Web of Science ®Google Scholar
• Wright DB, Horry R, Skagerberg EM. Functions for traditional and multilevel approaches to signal detection theory. Behav Res Methods. 2009;41:257–267.
   PubMed Web of Science ®Google Scholar
• Suresh K. An overview of randomization techniques: an unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011;4:8.
   PubMedGoogle Scholar
• Benitez-Parejo N, Del Águila MR, Pérez-Vicente S. Survival analysis and cox regression. Allergol Immunopathol. 2011;39:362–373.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kattan MW. Drawing nomograms with r: applications to categorical outcome and survival data. Ann Transl Med. 2017;5:211
   PubMed Web of Science ®Google Scholar
• Kattan MW, Gerds TA. A framework for the evaluation of statistical prediction models. Chest. 2020;158:S29–S38.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574.
   PubMed Web of Science ®Google Scholar
• Deng C, Wu S-G, Y T. Lung large cell neuroendocrine carcinoma: an analysis of patients from the surveillance, epidemiology, and end-results (seer) database. Med Sci Monit. 2019;25:3636.
   PubMed Web of Science ®Google Scholar
• Gu J, Gong D, Wang Y, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019;8:2979–2993.
   PubMed Web of Science ®Google Scholar
• Kinslow CJ, May MS, Saqi A, et al. Large-cell neuroendocrine carcinoma of the lung: a population-based study. Clin Lung Cancer. 2020;21:e99–e113.
   PubMed Web of Science ®Google Scholar
• Cao L, Li Z-W, Wang M, Zhang T-T, Bao B, Liu Y-P. Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a seer population-based study. PeerJ. 2019;7:e6539.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lei C, Zhang X, Cui Y, Che K, Shen H. Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Cancer. 2019;10:6422.
   PubMed Web of Science ®Google Scholar
• Zhang J-T, Li Y, Yan L-X, et al. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: a multi-center retrospective study. Lung Cancer. 2020;139:118–123.
   PubMed Web of Science ®Google Scholar
• Iyoda A, Hiroshima K, Moriya Y, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage IA pulmonary non–small cell carcinoma. J Thorac Cardiovasc Surg. 2006;132:312–315.
   PubMed Web of Science ®Google Scholar
• Shen Y, Hu F, Li C, et al. Clinical features and outcomes analysis of surgical resected pulmonary large-cell neuroendocrine carcinoma with adjuvant chemotherapy. Front Oncol. 2020;10:2659.
   Web of Science ®Google Scholar
• Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage iv non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488.
   PubMed Web of Science ®Google Scholar
• Le Treut J, Sault M, Lena H, et al. Multicentre Phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the gfpc 0302 study. Ann Oncol. 2013;24:1548–1552.
   PubMed Web of Science ®Google Scholar
• Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase ii study. J Thorac Oncol. 2013;8:980–984.
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the cocis meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692–1698. doi:10.1200/JCO.2011.40.4905
   PubMed Web of Science ®Google Scholar
• May MS, Kinslow CJ, Adams C, et al. Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States. Transl Lung Cancer Res. 2021;10:71.
   PubMed Web of Science ®Google Scholar
• Trikalinos NA, Tan BR, Amin M, Liu J, Govindan R, Morgensztern D. Effect of metastatic site on survival in patients with neuroendocrine neoplasms (nens). An analysis of seer data from 2010 to 2014. BMC Endocr Disord. 2020;20:1–10.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Castonguay M, Wilke D, et al. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. Curr Probl Cancer. 2019;43:54–65.
   PubMed Web of Science ®Google Scholar